EP1575971A4 - PROCESS FOR THE PREPARATION OF 3-NUCLEOSIDE PRODRUGS - Google Patents
PROCESS FOR THE PREPARATION OF 3-NUCLEOSIDE PRODRUGSInfo
- Publication number
- EP1575971A4 EP1575971A4 EP03814400A EP03814400A EP1575971A4 EP 1575971 A4 EP1575971 A4 EP 1575971A4 EP 03814400 A EP03814400 A EP 03814400A EP 03814400 A EP03814400 A EP 03814400A EP 1575971 A4 EP1575971 A4 EP 1575971A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- nucleoside
- free
- protection
- reaction
- methyl branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
Definitions
- nucleosides that have four non-hydrogen substituents in the 2' or 3 '-positions
- acylated forms of the nucleosides See for example, WO 01/90121 (USSN 09/864,078); WO 01/92282 (USSN 09/863,816); PCT/IB03/03901 (USSN 10/609,298); PCT/IB03/03246 (USSN
- the optionally protected branched nucleoside was then coupled with a suitable acyl donor, such as an acyl chloride and/or an acyl anhydride or an activated acid, in an appropriate protic or aprotic solvent and at a suitable reaction temperature, to provide the 2' or 3' prodrug of the branched nucleoside, optionally in the presence of a suitable coupling agent (see Synthetic Communications, 1978, 8(5): 327- 33; J Am. Chem. Soc, 1999, 121 (24): 5661-5; Bryant et al., Antimicrob. Agents
- a suitable acyl donor such as an acyl chloride and/or an acyl anhydride or an activated acid
- the nucleoside preferably was not protected, but was coupled directly to an alkanoic or amino acid residue via a carbodiimide-coupling reagent.
- a nucleoside with a protected organic acid in the presence of a coupling reagent (such as CDI), and a base (such as TEA), optionally in the presence of a base catalyst (such as DMAP), for example in a polar solvent (such as DMF and/or THF), results in the selective addition of the protected organic acid to the 3' -OH of the nucleoside, thereby forming a 3 '-prodrug of the nucleoside.
- a coupling reagent such as CDI
- a base such as TEA
- a base catalyst such as DMAP
- polar solvent such as DMF and/or THF
- a 2' or 3 '-branched nucleoside with a protected organic acid in the presence of a coupling reagent (such as CDI), base (such as TEA), optionally in the presence of a base catalyst (such as DMAP), and a polar solvent (such as THF and/or DMF) results in the addition of the protected organic acid selectively to the 3' -OH of the nucleoside, thereby forming a 3 '-prodrug of the nucleoside. Since the process occurs in only a single step, the time required for forming the prodrug product is significantly reduced from processes found in the prior art. In one embodiment of the present invention, the product yield is above 50%.
- the nucleoside with a free or reactive 3' -OH (or -SH) can be purchased or can be prepared by any published or unpublished means including standard reduction, oxidation, substitution and/or coupling techniques.
- the nucleoside is a 2' or 3 '-branched nucleoside.
- the nucleoside with a free 3' -OH (or -SH) is a 2'-deoxynucleoside such as 2'-deoxycytidine or 2'-deoxythymidine, which can be purchased or can be prepared by any published or unpublished means including standard reduction and coupling techniques.
- the 3 '-selectively acylated nucleoside can be prepared by reaction of the optionally protected organic acid with the nucleoside with a free 3'-OH (or -SH) in the presence of a coupling reagent and base(s).
- Suitable coupling reagents include EDC (1-
- the reagents can be added simultaneously or sequentially over a suitable period and temperature to allow the reaction to proceed at an acceptable rate without excessive side products.
- the optionally protected organic acid is stirred with the coupling reagent prior to addition of the nucleoside and/or base(s).
- the optionally protected organic acid such as an optionally protected amino acid, for example Boc-L-valine
- the coupling agent such as CDI. This reaction can be accomplished at any temperature that allows the reaction to proceed at an acceptable rate without promoting decomposition or excessive side products.
- some of the more volatile solvents e.g. THF
- base(s) e.g. TEA
- THF more volatile solvents
- base(s) e.g. TEA
- the 3 '-selectively esterified at the 3 '-position nucleoside can be reacted with a pharmaceutically acceptable inorganic or organic acid, such as HC1, in a solvent, such as a polar protic solvent, for example EtOH, to provide a pharmaceutically acceptable salt, such as a hydrochloride salt, as a final product.
- a pharmaceutically acceptable inorganic or organic acid such as HC1
- a solvent such as a polar protic solvent, for example EtOH
- the base is a purine base selected from the group consisting of N 6 -alkylpurines (including N-methyl purine), N 6 -acylpurines (wherein acyl is C(O)(alkyl, aryl, alkylaryl, or arylalkyl), N 6 -benzylpurine, N 6 - halopurine, N 6 -vinylpurine, N 6 -acetylenic purine, N 6 -acyl purine, N 6 -hydroxyalkyl purine, N 6 -thioalkyl purine, N 2 -alkylpurines, N 2 -alkyl-6-thiopurines, N 2 -alkylpurines, N 2 -alkyl-6-thiopurines, 5-azacytidinyl, guanine, adenine, hypoxanthine, 2,6- diaminopurine, and 6-chloropurine.
- N 6 -alkylpurines including N-methyl
- the base is a selected from the group consisting of:
- the 2'-C- methyl branched nucleoside to be selectively esterified at the 3 '-position is
- the 2'-C- methyl branched nucleoside to be selectively esterified at the 3 '-position is
- the 2'-C- methyl branched nucleoside to be selectively esterified at the 3 '-position is
- the 2'-C- methyl branched nucleoside to be selectively esterified at the 3 '-position is
- the 2'-C- methyl branched nucleoside to be selectively esterified at the 3 '-position is
- the 2'-C- methyl branched nucleoside to be selectively esterified at the 3 '-position is
- the 2'-C- methyl branched nucleoside to be selectively esterified at the 3 '-position is
- protected refers to a group that is added to an oxygen, nitrogen or phosphorus atom to prevent its further reaction or for other purposes.
- oxygen, nitrogen and phosphorus protecting groups are known to those skilled in the art of organic synthesis.
- alkaryl and alkylaryl refer to an alkyl group with an aryl substituent.
- aralkyl and arylalkyl refer to an aryl group with an alkyl substituent.
- non-natural amino acid refers to a carboxylic acid having an amino group terminus but that is not found in nature.
- the term is intended to embrace both D- and L-amino acids, and any tautomeric or stereoisomeric forms thereof.
- nucleoside base includes but is not limited to purine or pyrimidine bases.
- purine or pyrimidine base include, but are not limited to, adenine, N 6 -alkylpurines, N 6 -acylpurines (wherein acyl is C(O)(alkyl, aryl, alkylaryl, or arylalkyl), N 6 -benzylpurine, N 6 -halopurine, N 6 -vinylpurine, N 6 -acetylenic purine, N 6 - acyl purine, N 6 -hydroxyalkyl purine, N 6 -thioalkyl purine, N 2 -alkylpurines, N 2 -alkyl-6- thiopurines, thymine, cytosine, 5-fluorocytosine, 5-methylcytosine, 6-azapyrimidine, including 6-azacytosine, 2- and/or 4-mercaptopyrmidine, uracil, 5-halouracil
- the process of the present invention is not limited to the use of BOC as a protecting group.
- Other protecting groups such as, for example, substituted or unsubstituted silyl groups; substituted or unsubstituted ether groups like C-O-aralkyl, C-
- O-alkyl, or C-O-aryl O-alkyl, or C-O-aryl; aliphatic groups such as acyl or acetyl groups having an alkyl moiety that is straight-chained or branched; and any such groups that would not adversely affect the materials, reagents and conditions of the present invention as known to those of skill in the art and as taught by Greene et al., Protective Groups in Organic Synthesis, John Wiley and Sons, 2 nd Edition (1991), may be used.
- Any organic solvents such as, for example, toluene may replace acetonitrile.
- Triethylamine and tetrahydrofuran were removed under reduced pressure at 43°C.
- the solution then was cooled to 10°C and neutralized with acetic acid to a pH of 7.7.
- the mixture was diluted with methylene chloride (100 mL) and brine (100 mL). This mixture was agitated for 10 minutes, the layers were split, and the aqueous layer was back extracted with 2 x 100 mL of methylene chloride.
- the organic layer was extracted with a solution of 10% malonic acid in water (4 x 100 mL).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43615002P | 2002-12-23 | 2002-12-23 | |
US436150P | 2002-12-23 | ||
PCT/US2003/041603 WO2004058792A1 (en) | 2002-12-23 | 2003-12-23 | Process for the production of 3'-nucleoside prodrugs |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1575971A1 EP1575971A1 (en) | 2005-09-21 |
EP1575971A4 true EP1575971A4 (en) | 2008-03-05 |
Family
ID=32682350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03814400A Withdrawn EP1575971A4 (en) | 2002-12-23 | 2003-12-23 | PROCESS FOR THE PREPARATION OF 3-NUCLEOSIDE PRODRUGS |
Country Status (16)
Country | Link |
---|---|
US (1) | US20040181051A1 (es) |
EP (1) | EP1575971A4 (es) |
JP (1) | JP2006514038A (es) |
KR (1) | KR20050110611A (es) |
CN (1) | CN100335492C (es) |
AU (1) | AU2003300434A1 (es) |
BR (1) | BR0316868A (es) |
CA (1) | CA2511616A1 (es) |
IL (1) | IL169314A0 (es) |
MX (1) | MXPA05006865A (es) |
NO (1) | NO20053557L (es) |
NZ (1) | NZ540913A (es) |
PL (1) | PL377608A1 (es) |
RU (1) | RU2005123395A (es) |
WO (1) | WO2004058792A1 (es) |
ZA (1) | ZA200505040B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
NZ547204A (en) | 2000-05-26 | 2008-01-31 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses and pestiviruses |
KR20050088079A (ko) | 2002-11-15 | 2005-09-01 | 이데닉스 (케이만) 리미티드 | 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이 |
WO2004096149A2 (en) * | 2003-04-28 | 2004-11-11 | Idenix (Cayman) Limited | Industrially scalable nucleoside synthesis |
WO2005123087A2 (en) * | 2004-06-15 | 2005-12-29 | Merck & Co., Inc. | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase |
WO2006050161A2 (en) | 2004-10-29 | 2006-05-11 | Biocryst Pharmaceuticals, Inc. | Therapeutic furopyrimidines and thienopyrimidines |
EP1830871A1 (en) * | 2004-12-23 | 2007-09-12 | Novartis AG | Compositions for hcv treatment |
US8802840B2 (en) | 2005-03-08 | 2014-08-12 | Biota Scientific Management Pty Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
US7514410B2 (en) * | 2005-03-29 | 2009-04-07 | Biocryst Pharmaceuticals, Inc. | Hepatitis C therapies |
CA2622191A1 (en) * | 2005-09-22 | 2008-03-11 | Keshab Sarma | Selective o-acylation of nucleosides |
WO2007095269A2 (en) * | 2006-02-14 | 2007-08-23 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
EP2004634A1 (en) | 2006-04-04 | 2008-12-24 | F.Hoffmann-La Roche Ag | 3',5'-di-o-acylated nucleosides for hcv treatment |
WO2010015637A1 (en) * | 2008-08-06 | 2010-02-11 | Novartis Ag | New antiviral modified nucleosides |
CL2009002206A1 (es) | 2008-12-23 | 2011-08-26 | Gilead Pharmasset Llc | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. |
NZ593648A (en) | 2008-12-23 | 2013-09-27 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
EA201100851A1 (ru) | 2008-12-23 | 2012-04-30 | Фармассет, Инк. | Аналоги нуклеозидов |
PE20120013A1 (es) * | 2009-01-09 | 2012-02-02 | Univ Cardiff | Fosforamidato derivados de guanosina compuestos nucleosidos para tratamiento de infecciones virales |
BR112012024884A2 (pt) | 2010-03-31 | 2016-10-18 | Gilead Pharmasset Llc | síntese estereosseletiva de ativos contendo fósforo |
EA037868B1 (ru) | 2016-09-07 | 2021-05-28 | Атеа Фармасьютикалс, Инк. | 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний |
US20220033430A1 (en) * | 2018-11-25 | 2022-02-03 | Tnt Medical Corporation | Orally active prodrug of gemcitabine |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001090121A2 (en) * | 2000-05-23 | 2001-11-29 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus |
WO2004003000A2 (en) * | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | 1’-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3798209A (en) * | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
USRE29835E (en) * | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
FR2562543B1 (fr) * | 1984-04-10 | 1987-09-25 | Elf Aquitaine | Nouveaux phosphonites cycliques, leur preparation et applications |
NL8403224A (nl) * | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
US5223263A (en) * | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
GB8719367D0 (en) * | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US5194654A (en) * | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
US5463092A (en) * | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
CA2083961A1 (en) * | 1990-05-29 | 1991-11-30 | Henk Van Den Bosch | Synthesis of glycerol di- and triphosphate derivatives |
US5627165A (en) * | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
US5543390A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5149794A (en) * | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
US5256641A (en) * | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
US5543389A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
US5157027A (en) * | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
US5554728A (en) * | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
US5696277A (en) * | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
IL129126A0 (en) * | 1996-10-16 | 2000-02-17 | Icn Pharmaceuticals | Monocyclic l-nucleosides analogs and uses thereof |
US6248878B1 (en) * | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
US6472373B1 (en) * | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
BR9908270A (pt) * | 1998-02-25 | 2004-06-29 | Univ Emory | 2-fluoro-nucleosìdeos, composições farmacêuticas e seus usos |
US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
PL192364B1 (pl) * | 1998-06-08 | 2006-10-31 | Hoffmann La Roche | Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną |
WO2001018013A1 (en) * | 1999-09-08 | 2001-03-15 | Metabasis Therapeutics, Inc. | Prodrugs for liver specific drug delivery |
US6566365B1 (en) * | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
HUP0204092A3 (en) * | 1999-12-22 | 2005-02-28 | Metabasis Therapeutics Inc San | Novel bisamidate phosphononate prodrugs |
US6495677B1 (en) * | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
KR20030005197A (ko) * | 2000-02-18 | 2003-01-17 | 샤이어 바이오켐 인코포레이티드 | 뉴클레오시드유도체를 이용한 플라비바이러스 감염의 치료또는 예방 방법 |
DE60136620D1 (de) * | 2000-04-13 | 2009-01-02 | Pharmasset Inc | 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen |
WO2001081359A1 (en) * | 2000-04-20 | 2001-11-01 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
NZ547204A (en) * | 2000-05-26 | 2008-01-31 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses and pestiviruses |
US6875751B2 (en) * | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
EP2145965A1 (en) * | 2000-10-18 | 2010-01-20 | Pharmasset, Inc. | Multiplex quantification of nucleic acids in diseased cells |
EP1326594A2 (en) * | 2000-10-18 | 2003-07-16 | Schering Corporation | Ribavirin-pegylated interferon alfa hcv combination therapy |
CN1646141B (zh) * | 2000-10-18 | 2014-06-25 | 吉利德制药有限责任公司 | 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物 |
US7105499B2 (en) * | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
MXPA03006514A (es) * | 2001-01-22 | 2004-12-02 | Merck & Co Inc | Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico. |
GB0112617D0 (en) * | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
WO2003024461A1 (en) * | 2001-09-20 | 2003-03-27 | Schering Corporation | Hcv combination therapy |
JP2005522443A (ja) * | 2002-02-14 | 2005-07-28 | フアーマセツト・リミテツド | 改変フッ素化ヌクレオシド類似体 |
AU2003217863B9 (en) * | 2002-02-28 | 2009-10-29 | Biota Scientific Management Pty Ltd | Nucleotide mimics and their prodrugs |
US7247621B2 (en) * | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
EP1501850A2 (en) * | 2002-05-06 | 2005-02-02 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
AU2003248748A1 (en) * | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7094768B2 (en) * | 2002-09-30 | 2006-08-22 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
WO2004028481A2 (en) * | 2002-09-30 | 2004-04-08 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
KR20050088079A (ko) * | 2002-11-15 | 2005-09-01 | 이데닉스 (케이만) 리미티드 | 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이 |
TWI332507B (en) * | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
CA2509687C (en) * | 2002-12-12 | 2012-08-14 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
-
2003
- 2003-12-23 RU RU2005123395/04A patent/RU2005123395A/ru not_active Application Discontinuation
- 2003-12-23 AU AU2003300434A patent/AU2003300434A1/en not_active Abandoned
- 2003-12-23 JP JP2004562599A patent/JP2006514038A/ja active Pending
- 2003-12-23 MX MXPA05006865A patent/MXPA05006865A/es unknown
- 2003-12-23 NZ NZ540913A patent/NZ540913A/en unknown
- 2003-12-23 WO PCT/US2003/041603 patent/WO2004058792A1/en active Application Filing
- 2003-12-23 CA CA002511616A patent/CA2511616A1/en not_active Abandoned
- 2003-12-23 PL PL377608A patent/PL377608A1/pl not_active Application Discontinuation
- 2003-12-23 EP EP03814400A patent/EP1575971A4/en not_active Withdrawn
- 2003-12-23 CN CNB2003801098204A patent/CN100335492C/zh not_active Expired - Fee Related
- 2003-12-23 BR BR0316868-9A patent/BR0316868A/pt not_active IP Right Cessation
- 2003-12-23 KR KR1020057011749A patent/KR20050110611A/ko not_active Application Discontinuation
- 2003-12-23 US US10/746,395 patent/US20040181051A1/en not_active Abandoned
-
2005
- 2005-06-21 ZA ZA200505040A patent/ZA200505040B/en unknown
- 2005-06-21 IL IL169314A patent/IL169314A0/en unknown
- 2005-07-20 NO NO20053557A patent/NO20053557L/no not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001090121A2 (en) * | 2000-05-23 | 2001-11-29 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus |
WO2004003000A2 (en) * | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | 1’-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections |
Non-Patent Citations (1)
Title |
---|
See also references of WO2004058792A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2511616A1 (en) | 2004-07-15 |
CN100335492C (zh) | 2007-09-05 |
WO2004058792A1 (en) | 2004-07-15 |
PL377608A1 (pl) | 2006-02-06 |
KR20050110611A (ko) | 2005-11-23 |
AU2003300434A1 (en) | 2004-07-22 |
ZA200505040B (en) | 2006-04-26 |
NO20053557L (no) | 2005-09-08 |
IL169314A0 (en) | 2007-07-04 |
MXPA05006865A (es) | 2005-12-12 |
EP1575971A1 (en) | 2005-09-21 |
NZ540913A (en) | 2008-02-29 |
US20040181051A1 (en) | 2004-09-16 |
BR0316868A (pt) | 2005-10-25 |
RU2005123395A (ru) | 2006-01-27 |
CN1751058A (zh) | 2006-03-22 |
JP2006514038A (ja) | 2006-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2319853B1 (en) | Process for the production of 2'-branched nucleosides | |
US20040181051A1 (en) | Process for the production of 3'-nucleoside prodrugs | |
EP1773856B1 (en) | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives | |
AU2009329872B2 (en) | Synthesis of purine nucleosides | |
US7582748B2 (en) | Methods of manufacture of 2′-deoxy-β-L-nucleosides | |
JP2008507547A6 (ja) | アルキル置換された2−デオキシ−2−フルオロ−d−リボフラノシルピリミジン類及びプリン類及びそれらの誘導体の調製 | |
EP2734535A2 (en) | 2',3'-DIDEOXY-2'-alpha-FLUORO-2'-beta-C-METHYLNUCLEOSIDES AND PRODRUGS THEREOF | |
WO2015095305A1 (en) | Production of cyclic phosphate, phosphoramidate, thiophosphate, and phosphonate nucleoside compounds | |
US7595390B2 (en) | Industrially scalable nucleoside synthesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050627 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080131 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080430 |